GlassScriptPhysician profile
Howard Mark Ruskin
NPI 1619957669
$509.66
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $91.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $122.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.77 | 2019-2020 | |
| Genzyme Corporation | $48.42 | 2019 | |
| Upsher-Smith Laboratories LLC | $41.57 | 2019 | |
| Biogen, INC. | $35.82 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $32.19 | 2020 | |
| Ucb, INC. | $29.37 | 2020 | |
| Bausch Health US, LLC | $28.49 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.13 | 2019 | |
| Zyla Life Sciences, INC. | $20.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.97 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.42 | 2019 | |
| Assertio Therapeutics, INC. | $12.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Ruskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.